Amedisys (AMED) Competitors

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.

Does the media refer more to AMED or DVA?

In the previous week, DaVita had 3 more articles in the media than Amedisys. MarketBeat recorded 5 mentions for DaVita and 2 mentions for Amedisys. Amedisys' average media sentiment score of 1.14 beat DaVita's score of 0.66 indicating that Amedisys is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amedisys	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in AMED or DVA?

94.4% of Amedisys shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.1% of Amedisys shares are held by insiders. Comparatively, 2.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has higher valuation & earnings, AMED or DVA?

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amedisys	$2.37B	1.34	-$9.75M	$2.71	35.79
DaVita	$12.97B	0.79	$936.34M	$10.09	13.49

Which has more risk and volatility, AMED or DVA?

Amedisys has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Do analysts prefer AMED or DVA?

Amedisys presently has a consensus price target of $100.75, suggesting a potential upside of 3.88%. DaVita has a consensus price target of $164.50, suggesting a potential upside of 20.86%. Given DaVita's higher possible upside, analysts plainly believe DaVita is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
DaVita	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community favor AMED or DVA?

DaVita received 1 more outperform votes than Amedisys when rated by MarketBeat users. Likewise, 61.10% of users gave DaVita an outperform vote while only 58.68% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Amedisys	Outperform Votes 497 58.68%	Underperform Votes 350 41.32%
DaVita	Outperform Votes 498 61.10%	Underperform Votes 317 38.90%

Is AMED or DVA more profitable?

DaVita has a net margin of 7.31% compared to Amedisys' net margin of 3.57%. DaVita's return on equity of 115.48% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amedisys	3.57%	12.20%	6.74%
DaVita	7.31%	115.48%	4.94%

Summary

DaVita beats Amedisys on 10 of the 17 factors compared between the two stocks.